Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H5O7.3Ag |
| Molecular Weight | 512.7043 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ag+].[Ag+].[Ag+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=QUTYHQJYVDNJJA-UHFFFAOYSA-K
InChI=1S/C6H8O7.3Ag/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
| Molecular Formula | Ag |
| Molecular Weight | 107.8682 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H5O7 |
| Molecular Weight | 189.0997 |
| Charge | -3 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.purebio.com/assets/001/5202.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19278981http://google.com/patents/CN102923966BThe legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738Curator's Comment: description was created based on several sources, including
https://www.drugs.com/monograph/silver-nitrate.html |
https://www.ncbi.nlm.nih.gov/pubmed/18245232
Sources: https://www.purebio.com/assets/001/5202.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/19278981http://google.com/patents/CN102923966BThe legal airborne permissible exposure limit (PEL) is 11 mg/m^2 averaged over an 8-hour workshift.https://www.ncbi.nlm.nih.gov/pubmed/26897901https://www.ncbi.nlm.nih.gov/pubmed/25781988https://www.ncbi.nlm.nih.gov/pubmed/20429870https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+2930 | https://www.ncbi.nlm.nih.gov/pubmed/11294738
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/monograph/silver-nitrate.html |
https://www.ncbi.nlm.nih.gov/pubmed/18245232
Silver iodide is an inorganic compound with the formula AgI. It is used as a photosensitive agent in photography, as a local antiseptic, as a chemical intermediate, and in cloud seeding for rain-making. The major hazards encountered in the use and handling of silver iodide stem from its toxicologic properties. Effects from exposure may include skin rashes, conjunctivitis, argyria (a permanent ashen-gray discoloration of skin, conjunctiva, and internal organs), headache, fever, hypersensitivity, laryngitis, and bronchitis.
Originator
Sources: Vestsi Akademii Navuk BSSR, Seryya Khimichnykh Navuk, Issue 2, Pages 69-73, Journal, 1990https://www.ncbi.nlm.nih.gov/pubmed/20429870
Curator's Comment: The medical uses of silver date back to at least the time of Hippocrates
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26897901 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0034505 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24373700 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
|||
Target ID: GO:0071292 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245232 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
| Primary | Advantage Arrest Silver Diamine Fluoride Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
| Primary | Colloidal silver iodide Approved UseSolution containing 5 to 49% of colloidal silver iodide have been employed in the treatment of infections of the mucous membranes. Ointments, usually containing 5%, have been used in inflammatory conditions of the eye, ear, and nose. |
|||
| Palliative | Unknown Approved UseAntiseptic Wound Cauterization |
|||
| Primary | Unknown Approved UseProphylaxis of gonococcal ophthalmia neonatorum. AAP recommends use of topical silver nitrate, povidone-iodine, or possibly erythromycin for prophylaxis of nongonococcal nonchlamydial conjunctivitis in neonates, ideally administered shortly after birth. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Directional growth of Ag nanorod from polymeric silver cyanide: A potential substrate for concentration dependent SERS signal enhancement leading to melamine detection. | 2017-08-05 |
|
| The antifungal effects and mechanical properties of silver bromide/cationic polymer nano-composite-modified Poly-methyl methacrylate-based dental resin. | 2017-05-08 |
|
| UCSF Protocol for Caries Arrest Using Silver Diamine Fluoride: Rationale, Indications and Consent. | 2016-01 |
|
| An alternate technique of care using silver fluoride followed by stannous fluoride in the management of root caries in aged care. | 2015-12-22 |
|
| A novel silver iodide metalo-drug: experimental and computational modelling assessment of its interaction with intracellular DNA, lipoxygenase and glutathione. | 2014-04-22 |
|
| Development of silica-coated silver iodide nanoparticles and their biodistribution. | 2012-12 |
|
| Cleaning and decontamination efficacy of wiping cloths and silver dihydrogen citrate on food contact surfaces. | 2012-07 |
|
| Topical antimicrobials for burn wound infections. | 2010-06 |
|
| Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. | 2008-04 |
|
| Photocatalytic degradation of pathogenic bacteria with AgI/TiO2 under visible light irradiation. | 2007-04-24 |
|
| Comparative efficacy of hand hygiene agents in the reduction of bacteria and viruses. | 2005-03 |
|
| New disinfection and sterilization methods. | 2001-04-11 |
|
| A chemically intelligent antimicrobial coating for urologic devices. | 2000-02 |
|
| Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and in the Ames/microsome test. | 1998 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.purebio.com/assets/001/5202.pdf
Curator's Comment: Toxicity data
Topical as a 1:80 dilution (30 ppm ionic silver).
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27775827
10 mkl volume of undiluted human norovirus 20% faecal suspension was mixed with 90 mkl of SDC (Silver Dihydrogen Citrate) for various contact times (15, 30, 60, 120, 300, 600 and 1800 s). At each sampling time point, 20 mkl of this solution was added to 180 mkl of 10% solution of Dey/Engley (D/E) neutralizing broth (Thermo Fisher Scientific, Waltham, MA). Samples were aliquoted and frozen at -80°C prior to nucleic acid extraction.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:45:01 GMT 2025
by
admin
on
Mon Mar 31 18:45:01 GMT 2025
|
| Record UNII |
CKA421A1J7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 310.548
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
204-786-8
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
1306066
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
CKA421A1J7
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
DTXSID70889420
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
101599
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
CKA421A1J7
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
126-45-4
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
DB11233
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | |||
|
m9920
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000182572
Created by
admin on Mon Mar 31 18:45:01 GMT 2025 , Edited by admin on Mon Mar 31 18:45:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |